MedPath

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Outcome of Resection for Colorectal Cancer

Not Applicable
Conditions
Laparoscopy
First Posted Date
2019-02-12
Last Posted Date
2019-02-12
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
1300
Registration Number
NCT03837782
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

The MDA Test to Differentiate of Benign and Malignant Pulmonary Nodules

Conditions
Pulmonary Nodule, Solitary
First Posted Date
2019-01-02
Last Posted Date
2019-01-02
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
200
Registration Number
NCT03790735
Locations
🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection

Phase 3
Conditions
Cholangiocarcinoma
Gall Bladder Carcinoma
Interventions
First Posted Date
2018-12-19
Last Posted Date
2018-12-19
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
460
Registration Number
NCT03779035
Locations
🇨🇳

Tianjin Medical University Cancer Insititute and Hospital, Tianjin, Tianjin, China

A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization

Phase 2
Conditions
HPV
Cervical Intraepithelial Neoplasia
First Posted Date
2018-11-19
Last Posted Date
2018-11-19
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
78
Registration Number
NCT03745846

Effect of Radiation and Its Timing on Breast Reconstruction in Chinese Patients

Conditions
Breast Cancer
First Posted Date
2018-11-16
Last Posted Date
2018-11-16
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
1344
Registration Number
NCT03743324

Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients

Not Applicable
Conditions
Breast Neoplasms
Interventions
Drug: Cefazolin/clindamycin
First Posted Date
2018-11-15
Last Posted Date
2018-11-15
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
291
Registration Number
NCT03742908
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Phase 2
Completed
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2018-11-09
Last Posted Date
2021-03-15
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
60
Registration Number
NCT03736837
Locations
🇨🇳

Hebei Provincial People's Hospital, Shijiazhuang, Hebei, China

🇨🇳

Neimenggu Autonomous Region People's Hospital, Hohhot, Neimenggu, China

🇨🇳

Neimenggu Medical University Affiliated Hospital, Hohhot, Neimenggu, China

and more 2 locations

A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Cancer

Phase 3
Conditions
Stage II Esophageal Cancer
Stage III Esophageal Cancer
First Posted Date
2018-10-16
Last Posted Date
2018-10-16
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
220
Registration Number
NCT03708042

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Not Applicable
Conditions
Esophageal Cancer
Interventions
Radiation: IMRT or VMAT
First Posted Date
2018-09-14
Last Posted Date
2019-01-09
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
20
Registration Number
NCT03671265
Locations
🇨🇳

Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing

Completed
Conditions
NSCLC
First Posted Date
2018-08-01
Last Posted Date
2018-08-07
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
513
Registration Number
NCT03609918
© Copyright 2025. All Rights Reserved by MedPath